MedTrace Logo

Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection

NCT02711176 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2017-06-08

No results posted yet for this study

Summary

This study is conducted to investigate whether the efficacy of single-dose triple therapy (Esomeprazole 40 mg, Tinidazole 1 g, and Levofluxacine 500 mg) for 14 days is superior to double-dose lansoprazole 30 mg, amoxicillin 1 g and clarithromycin 500 mg for 14 days in the treatment of H pylori infection.

Conditions

  • Helicobacter Infection

Interventions

DRUG

Nexium

Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily

DRUG

Tinafas

Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily

DRUG

Tavanex

Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily

DRUG

Lanzol

Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily

DRUG

Klacid

Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily

DRUG

Iramox

Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily

Sponsors & Collaborators

  • Zahra Vahdat Shariatpanahi

    lead OTHER

Principal Investigators

  • Shaahin Shahbazi, MD · Assistant Professor, Ilam University of Medical Sciences,Head of Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-03-27
Completion
2017-03-27

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02711176 on ClinicalTrials.gov